Lisa La on the Next 5 Years in Multiple Myeloma Research

Video

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed what she hopes will occur in multiple myeloma research over the next 5 years.

Transcription:

Hopefully we find a cure for myeloma. The director that I worked with at Sinai, I remember interviewing someone with him and the coordinator asked him specifically, “What is your goal in myeloma? You’re doing all these things. You've dedicated the last 20, 30 years of your life to myeloma into your patients. Your patients have your cell phone number, they call you at your house.” And he said, “To find a cure, as simple as that, why else would I dedicate my life to myeloma?”

And that resonated with me, you know, and I think that his passion and along with other oncologists that I've met along the way, who have focused on myeloma really, really have a passion and hoping to find a cure. And that's what I hope, that we are one step closer each year, and hopefully in 5 years we would have some sort of cure. But patients are living a lot longer, again, from 10 years ago when I started to now, but you know, we have to keep pushing the boundaries to see what else we can do.

Recent Videos
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content